EP0186522A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Cancer-specific DNA
Assignee: Sankyo Co Ltd
•
Filing: 1985-12-30
•
Granted: —
•
Expires: 2005-12-30
Abstract
Abstract Using genetic engineering techniques, cDNA can be obtained which is expressed only in cancer cells, and not in non-cancerous, normal cells. Such DNA can be used to prepare nucleic acid probes for cancer. An example of the novel DNA has the base sequence:
Inventors
- 👤 Hideya Endo
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 18:54
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883; C12Q1/6886; C12Q2600/00; C12Q2600/158
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
4 words
A cancer-specific DNA sequence.
Claim 2
Dependent Claim
4 words
A cancer-specific DNA sequence.
Claim 3
Dependent Claim
48 words
A DNA sequence comprising: (i) the base sequence (I): (ii) a base sequence which functionally is substantially homologous with the base sequence (I) defined at (i); or (iii) a base sequence which will hybridize with at least part of the base sequence (I) defined at (i) or (ii).
Claim 4
Dependent Claim
48 words
A DNA sequence comprising: (i) the base sequence (I): (ii) a base sequence which functionally is substantially homologous with the base sequence (I) defined at (i); or (iii) a base sequence which will hybridize with at least part of the base sequence (I) defined at (i) or (ii).
Claim 5
Dependent Claim
54 words
A double-stranded DNA which comprises: a first strand, comrpising the DNA sequence (I) defined at (i) in claim 2 or a DNA sequence defined at (ii) in claim 2, and a second strand which is a substantially complementary DNA sequence and which is a DNA sequence as defined at (iii) in claim 2 .
Claim 6
Dependent Claim
11 words
An RNA sequence coded by the double-stranded DNA of claim 3.
Claim 7
Dependent Claim
12 words
A recombinant plasmid including a double-stranded DNA according to claim 3 .
Claim 8
Dependent Claim
18 words
6, A recombinant plasmid according to claim 5, further including an expression promoter for the said double-stranded DNA.
Claim 9
Dependent Claim
19 words
A labelled gene probe which comprises a labelled form of a DNA sequence according to claim 1 or 2.
Claim 10
Dependent Claim
17 words
A labelled gene probe which comprises a labelled form of an RNA sequence according to claim 4.
Claim 11
Dependent Claim
16 words
A labelled gene probe according to claim 7 or 8, wherein the label is a radiolabel.
Claim 12
Dependent Claim
32 words
A method of testing for cancer, wherein a sample of RNA or denatured DNA is incubated with a labelled gene probe according to claim 7, 8 or 9, and examined for hybridization.
Claim 13
Dependent Claim
76 words
A process for producing a cancer-specific DNA, which comprises the steps of: (a) obtaining RNA from a cancer cell; (b) synthesizing single-stranded cDNA complementary to the RNA; (c) producing double-stranded DNA from the single stranded cDNA; (d) inserting the double-stranded DNA into a vector to give a recombinant DNA: (e) transforming a host with the recombinant DNA; (f) screening the transformed host for cancer-specific DNA; and (g) isolating the desired cancer-specific DNA from the cloned host.
Claim 14
Dependent Claim
76 words
A process for producing a cancer-specific DNA, which comprises the steps of: (a) obtaining RNA from a cancer cell; (b) synthesizing single-stranded cDNA complementary to the RNA; (c) producing double-stranded DNA from the single stranded cDNA; (d) inserting the double-stranded DNA into a vector to give a recombinant DNA: (e) transforming a host with the recombinant DNA; (f) screening the transformed host for cancer-specific DNA; and (g) isolating the desired cancer-specific DNA from the cloned host.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.